Browsing by Author "Tosun, M"
Now showing 1 - 8 of 8
Results Per Page
Sort Options
Item Effects of isotretinoin on spermatogenesis of ratsGencoglan, G; Tosun, MObjectives: We evaluated time- and dose-dependent effects of isotretinoin on spermatogenic activity by apoptosis, cyclin D1, E2F, p53 expressions, and Johnsen''s scores. Methods: The rats were divided into three groups. In the 1st group (n == 18), 1 mg/mL/day and in the 2nd group (n == 18) 2 mg/mL/day isotretinoin were administered for 21 days. Flower oil was given to the 3rd (n == 6) control group. On the 7th (groups 1a and 2a), 14th (groups 1b and 2b), and 21st (groups 1c and 2c) days, six rats from the 1st group and six rats from the 2nd group were sacrificed and bilateral orchiectomy was done. Results: The number of cyclin D1 and E2F-positive cells decreased nonsignificantly parallel to days in the 1st group, whereas there was a statistically significant decrease in the 2nd group for the same cells. The p53-positive cells in groups 1c and 2c were increased significantly. Conclusions: Further studies on the effects of retinoids on spermatogenesis should be conducted. It may be wise to administer contraception to male patients, especially during high-dose and long-term retinoid therapy.Item Isotretinoin-induced Effects of Mast Cells on Wound HealingGencoglan, G; Tosun, M; Gencoglan, OWound healing is a complex process, and the role of retinoids in wounds is confusing and controversial. In this study, the authors aimed to evaluate the role of oral isotretinoin on mast cells, collagen production and remodeling in the wound healing process. In the first group 2 mg/kg/day isotretinoin dissolved in sunflower oil were administrated for 28 days. In the second group, only sunflower oil was administered. At the end of first week, four incisions were made on rats' back. In the seventh (group la and 2a), fourteenth (group 1b and 2b) and twenty-first (group 1c and 2c) days, the skin biopsies were taken from around of the incision areas from both groups. The authors revealed that isotretinoin administration permanently accelerates mast cell accumulation parallel to days in the wound area. The histological features of wound healing in isotretinoin administered rats were faster and better than the group 2.Item Epidemiological characteristics of different types of adult acne in Turkey: a prospective, controlled, multicenter studyKutlu, Ö; Karadag, AS; Demirseren, DD; Iyidal, AY; Tosun, M; Kalkan, G; Polat, M; Kemeriz, F; Türkoglu, Z; Erdogan, HK; Aktürk, AS; Alyamaç, G; Özden, HK; Kiliç, S; Kilinç, F; Akbulut, TO; Ermertcan, AT; Saricaoglu, H; Cemil, BC; Kayiran, MA; Aksoy, H; Alpsoy, EIntroduction: Acne occurring in adults over the age of 25 years is known as acne tarda or adult acne. Three types of adult acne are recognized: persistent, late-onset, and recurrent acne. Most studies do not compare the characteristics between the three vari-ants. In addition, little is known about adult acne in males. This study describes the epidemiological factors of adult acne and investigates certain triggering factors by sex and different types of adult acne. Methods: A multicenter, prospective, descriptive study was conducted. Patients with adult acne and an acne-free control group were compared regarding medical history, family history, smoking and drinking habits, and dietary factors. In addition, triggering and prognostic factors were investigated by sex and three different types of acne: persistent, late-onset, and recurrent acne. Results: The participants included 944 (88.56%) female and 122 (11.44%) male patients with adult acne, and 709 (73.85%) female and 251 (26.15%) male control patients. The consumption of crackers, chocolate, and pasta was significantly more common in the acne group than in the control group (p = 0.017, 0.002, and 0.040, respectively). Male patients with adult acne had a significantly longer disease duration than female patients with adult acne (p = 0.024). The most common type of acne was recurrent acne, followed by persistent and late-onset acne. Among patients with persistent acne, 14.5% had polycystic ovary syndrome (PCOS), whereas 12.2% of patients with recurrent acne and 11.1% of patients with late-onset acne had PCOS. Severe acne was more com-mon in the persistent acne type (28.13%). The cheek (59.90%) was the most common involvement area, and stress (55.23%) was the most common triggering factor regardless of sex. Conclusions: Although adult female and male patents with adult acne share similar triggering factors, the involvement areas can differ, which may indicate the additional hormonal etiology of female adult acne. Further epidemiological studies on adult acne in both sexes may illuminate the pathogenesis of the disease, thus making possible the development of new treatment strategies.Item Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-StudyEskiyurt, N; Irdesel, J; Sepici, V; Ugurlu, H; Kirazli, Y; Ardiç, F; Bütün, B; Akyüz, G; Cerrahoglu, L; Sendur, ÖF; Yalçin, P; Öncel, S; Saridogan, M; Sarpel, T; Tosun, M; Kutsal, YG; Senel, K; Gürsoy, S; Cantürk, F; Demir, H; Özdener, F; Öncel, HAim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSATQ), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7 +/- 9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered YES to at least one CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3 +/- 17.7 points), quality of life (10.4 +/- 20.4 points), overall satisfaction (11.9 +/- 22.7 points), and side effects (3.3 +/- 18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing schedule and 99.0% were compliant (>= 80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment. (Turkish Journal of Osteoporosis 2012; 18: 1-7)Item A CANDIDATE INDENTIFICATION QUESTIONNAIRE FOR PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS SWITCHED FROM TREATMENT WITH A DIALY OR WEEKLY BISHPOSPHONATE TO ONCE-MONTHLY IBANDRONATE-BONCURE: RESULTS OF TURKISH SUB-STUDYEskiyurt, N; Sendur, OF; Yalcin, P; Oncel, S; Saridogan, M; Sarpel, T; Tosun, M; Kutsal, YG; Senel, K; Gursoy, S; Canturk, F; Irdesel, J; Demir, H; Ozdener, F; Oncel, H; Serpici, V; Ugurlu, H; Kirazli, Y; Ardic, F; Butun, B; Akyuz, G; Cerrahoglu, LItem Evaluation of abdominal computed tomography findings in patients with COVID-19: a multicenter studyOnur, MR; Özbay, Y; Idilman, I; Karaosmanoglu, AD; Ramadan, SU; Barlik, F; Aydin, S; Odaman, H; Altay, C; Akin, IB; Dicle, O; Appak, O; Gülpinar, B; Erden, A; Kula, S; Çoruh, AG; Öz, DK; Kul, M; Uzun, C; Karavas, E; Levent, A; Artas, H; Eryesil, H; Solmaz, O; Kaygusuz, TO; Farasat, M; Kale, AB; Düzgün, F; Pekindil, G; Apaydin, FD; Duce, MN; Balci, Y; Esen, K; Kahraman, AS; Karaca, L; Özdemir, ZM; Kahraman, B; Tosun, M; Nural, MS; Camlidag, I; Onar, MA; Balli, K; Güler, E; Harman, M; Elmas, NZ; Öztürk, C; Güngör, O; Herek, D; Yagci, AB; Erol, C; Seker, M; Islek, I; Can, Y; Aslan, S; Bilgili, MYK; Göncüoglu, A; Keles, H; Sarikaya, PZB; Bakir, B; Kartal, MGD; Durak, G; Oguzdogan, GY; Alper, F; Yalçin, A; Gürel, S; Alan, B; Gündogdu, E; Aydin, N; Cansu, A; Kus, CC; Tuncer, EO; Piskin, FC; Er, HC; Degirmenci, B; Özmen, MN; Kantarci, M; Karçaaltincaba, MPURPOSETo evaluate the frequency of abdominal computed tomography (CT) findings in patients with coronavirus disease-2019 (COVID-19) and interrogate the relationship between abdominal CT findings and patient demographic features, clinical findings, and laboratory test results as well as the CT atheroscle-rosis score in the abdominal aorta.METHODSThis study was designed as a multicenter retrospective study. The abdominal CT findings of 1.181 patients with positive abdominal symptoms from 26 tertiary medical centers with a positive polymerase chain-reaction test for severe acute respiratory syndrome coronavirus 2 were reviewed. The frequency of ischemic and non-ischemic CT findings as well as the association between CT findings, clinical features, and abdominal aortic calcific atherosclerosis score (AA-CAS) were recorded.RESULTSIschemic and non-ischemic abdominal CT findings were detected in 240 (20.3%) and 328 (27.7%) patients, respectively. In 147 patients (12.4%), intra-ab-dominal malignancy was present. The most frequent ischemic abdominal CT findings were bowel wall thickening (n = 120; 10.2%) and perivascular infil-tration (n = 40; 3.4%). As for non-ischemic findings, colitis (n = 91; 7.7%) and small bowel inflammation (n = 73; 6.2%) constituted the most frequent disease processes. The duration of hospital stay was found to be higher in patients with abdominal CT findings than in patients without any positive findings (13.8 & PLUSMN; 13 vs. 10.4 & PLUSMN; 12.8 days, P < 0.001). The frequency of abdominal CT findings was significantly higher in patients who did not survive the infection than in patients who were discharged after recovery (41.7% vs. 27.4%, P < 0.001). Increased AA-CAS was found to be associated with a higher risk of ischemic conditions in abdominal CT examinations.CONCLUSIONAbdominal symptoms in patients with COVID-19 are usually associated with positive CT findings. The presence of ischemic findings on CT correlates with poor COVID-19 outcomes. A high AA-CAS is associated with abdominal ischemic findings in patients with COVID-19.Item A candidate-identification questionnaire for patients with postmenopausal osteoporosis switched from treatment with a daily or weekly bisphosphonate to once-monthly ibandronateKutsal, YG; Eskiyurt, N; Irdesel, J; Sepici, V; Ugurlu, H; Kirazli, Y; Ardic, F; Korsic, M; Vlak, T; Grlickov, M; Temelkova, SM; Lazarov, M; Pilipovic, N; Popovic, V; Dimic, A; Kovacev, B; Ruci, D; Tafaj, A; Kucukalic-Selimovic, E; Avdic, D; Seleskovic, H; Pejicic, S; Butun, B; Akyuz, G; Cerrahoglu, L; Sendur, OF; Yalcin, P; Oncel, S; Saridogan, M; Sarpel, T; Tosun, M; Senel, K; Gursoy, S; Cantürk, F; Demir, H; Miskic, B; Krpan, D; Skreb, F; Grazio, S; Crncevic-Orlic, Z; Ozdener, F; Oncel, HItem The molecular mechanism of etanercept, an anti-tumour necrosis factor-a receptor-fusion protein, in the treatment of acute generalized exanthematous pustulosisGencoglan, G; Tosun, M; Aktepe, FIntroduction: Acute generalized exanthematous pustulosis (AGEP) is one of the severe adverse cutaneous drug reactions. In its pathophysiology, releasing of tumour necrosis factor-alpha (TNF-) is very important. Therefore, treatment with an anti-TNF- receptor-fusion protein, such as etanercept, may be effective. Objective: To present a case and evaluate the molecular mechanism of etanercept in the treatment of AGEP. Case: A 53-year-old woman with multiple disseminated pustules and a rash on the upper part of her back, which was progressively worsening and spreading to approximately 60-70% of the skin on her back, and fever (38.7 degrees C), was admitted to our department. After etanercept treatment, all the symptoms were rapidly improved and the patient's skin practically cleared within 5 days. Biopsy samples taken from this patient with AGEP before and after etanercept treatment were stained immunohistochemically with p53 and bcl-2 antibodies and also an apoptosis detection kit. Results: In epidermis, increasing p53 expression-related apoptosis and decreasing bcl-2 expression was detected. However, after etanercept treatment, p53 expression-related apoptosis decreased and bcl-2 expression increased. Conclusion: Because TNF- stimulated inflammation and also p53-related apoptosis occurs in AGEP, a TNF- blocking agent such as etanercept may be effective for quick treatment.